Septerna, Inc. (NASDAQ:SEPN) CFO Acquires $57,855.00 in Stock

Septerna, Inc. (NASDAQ:SEPN - Get Free Report) CFO Gil M. Labrucherie bought 10,500 shares of the business's stock in a transaction that occurred on Wednesday, February 19th. The shares were acquired at an average price of $5.51 per share, with a total value of $57,855.00. Following the completion of the transaction, the chief financial officer now directly owns 10,500 shares of the company's stock, valued at $57,855. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Septerna Stock Down 3.7 %

NASDAQ:SEPN traded down $0.21 on Tuesday, reaching $5.52. 451,746 shares of the company's stock traded hands, compared to its average volume of 586,010. The stock's 50-day moving average is $17.46. Septerna, Inc. has a 12 month low of $4.17 and a 12 month high of $28.99.

Institutional Trading of Septerna

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC bought a new stake in shares of Septerna during the fourth quarter valued at approximately $25,000. New York State Common Retirement Fund purchased a new position in Septerna during the fourth quarter valued at $32,000. Legal & General Group Plc bought a new stake in Septerna in the 4th quarter valued at $42,000. Summit Investment Advisors Inc. purchased a new stake in Septerna in the 4th quarter worth $45,000. Finally, BNP Paribas Financial Markets purchased a new position in shares of Septerna during the fourth quarter valued at about $52,000.

Remove Ads

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on SEPN shares. TD Cowen started coverage on Septerna in a report on Tuesday, November 19th. They issued a "buy" rating on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $50.00 price objective on shares of Septerna in a research report on Tuesday, February 11th. JPMorgan Chase & Co. began coverage on shares of Septerna in a report on Tuesday, November 19th. They issued an "overweight" rating and a $38.00 target price for the company. Finally, Wells Fargo & Company downgraded shares of Septerna from an "overweight" rating to an "equal weight" rating and lowered their price target for the company from $43.00 to $14.00 in a report on Tuesday, February 18th.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.